Should I buy Insulet Corporation (PODD) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (383 calls tested). It aims for $190 (+38 %), call made on October 13, 2026, maturing on October 13, 2027 (1 d ago).
Firm-by-firm track record on Insulet Corporation
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| BTIG | 89 % | +48.0 % | 9 | $235 +70% |
| Jefferies | 67 % | +30.0 % | 9 | $190 +38% |
| JP Morgan | 75 % | +24.6 % | 8 | $152 +10% |
| Canaccord Genuity | 67 % | +21.3 % | 15 | $179 +30% |
| Raymond James | 54 % | +14.2 % | 26 | $360 +161% |
| Citigroup | 67 % | +13.3 % | 9 | $172 +25% |
| Wells Fargo | 40 % | -7.9 % | 5 | $144 +4% |
| Oppenheimer | 40 % | -15.6 % | 5 | $210 +52% |
✅ Reasons to believe
- Median price target $175, i.e. +27% from the current price ($138).
- The most reliable firm on PODD, UBS (100% hit rate, 3 scored calls), targets $150 (call made on August 6, 2026, maturing on August 6, 2027) (+9%) in its most recent call.
- 5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 20 ratings, 10 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on PODD
Median target $175 (+27%) · 20 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Insulet Corporation now?
We won't decide for you. The facts: 50% of analysts rate it a buy, median target $175 (+27%), and UBS (most reliable on PODD, 100%) targets $150. Weigh that against valuation (P/E ~26). This is not personalized advice.
Is it too late to invest in Insulet Corporation?
Not according to analysts: the median target ($175) is still +27% above the current price ($138) (most reliable on PODD: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Insulet Corporation still worth investing in?
It depends on the gap between the price ($138) and its estimated value: analysts target $175 on median (+27%), with 50% buys (most reliable on PODD: UBS, 100%). Cross-check with their real reliability on PODD and the cautions above. Information, not advice.
What's the main risk in buying PODD?
The consensus is not unanimous: of 20 ratings, 10 are neutral.
→ Go deeper: the full Insulet Corporation profile (consensus, analyst reliability, price target, performance).